Oxidation inhibits iron-induced blood coagulation

Current Drug Targets

Volumn 14, Issue 1, 2013, Pages 13-19

  Pretorius, Etheresia ^a   Bester, Janette ^a   Vermeulen, Natasha ^a   Lipinski, Boguslaw ^b  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Blood coagulation; Fibrinogen; Hydroxyl radical; Iron; Oxidation

Indexed keywords

FERRIC ION; FIBRINOGEN; HYDROGEN PEROXIDE; METHYLENE BLUE; SALICYLIC ACID; SODIUM SELENITE; THROMBIN;

ARTICLE; BLOOD CLOTTING; CELL ULTRASTRUCTURE; CONTROLLED STUDY; ERYTHROCYTE; HUMAN; OXIDATION; SCANNING ELECTRON MICROSCOPY; THROMBOCYTE RICH PLASMA;

EID: 84876715245     PISSN: 13894501     EISSN: 18735592     Source Type: Journal    
DOI: 10.2174/138945013804806541     Document Type: Article

References (30)

1. Kannel WB, Wolf PA, Castelli WP, D'Agnostino RB. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA 1987; 258(9): 1183-6.
2. Duguid JB. Thrombosis as a factor in the pathogenesis of coronary atherosclerosis. J Pathol Bacteriol 1946; 58: 207-12.
3. Smith EB. Fibrin deposition and fibrin degradation products in atherosclerotic plaques. Thromb Res 1994; 75: 329-35.
4. Undas A, Kolarz M, Kopeć G, Tracz W. Altered fibrin clot properties onlong-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial Transplant 2008; 23: 2010-5.
5. Longstaff C, Thelwell C, Williams SC, Silva MMCG, Szabo L, Kolev K. The interplay between tissue plasminogen activator domains and fibrin structures in the regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011; 117: 661-8.
6. Saraf S, Christopoulos C, Salha IB, Sctott DJ, Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. J Am Coll Cardiol 2010; 55: 2107-15.
7. Lipinski B. Modification of fibrin structure as a possible cause of thrombolytic resistance. J Thromb Thrombolysis 2010; 29: 296-8.
8. Pretorius E, Swanepoel AC, Oberholzer HM, van der Spuy WJ, Duim W, Wessels PF. A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke. J Thromb Thrombolysis 2011; 31: 507-13.
9. Lipinski B, Pretorius E, Oberholzer HM, van der Spuy WJ. Iron enhances generation of fibrin fibers in human blood: Implications for pathogenesis of stroke. Microsc Res Tech 2012; 75(9): 1185-90.
10. Kruszewski M. The role of labile iron pool in the cardiovascular disease. Acta Biochem Pol. 2004; 51: 471-80.
11. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron. Arch Toxicol 2010; 84: 825-89.
12. Franchini M, Targher G, Montagnana M, Lippi G. Iron and thrombosis. Ann Hematol 2008; 87: 167-73.
13. Lipinski B, Pretorius E. Novel pathway of iron-induced blood coagulation: Implications for Diabetes Mellitus and its complications. Pol Arch Med Wew 2012; 122: 115-22.
14. Lipinski B. Hydroxyl radical and its scavengers in health and disease. Oxid Med Cell Longev 2011; 2011: 809696.
15. Lipinski B, Pretorius E, Oberholzer HM, van der Spuy WJ. Interaction of fibrin with red blood cells: the role of iron. Ultrastruct Pathol 2011; 36: 79-84.
16. Zmijewski JW, Lorne E, Tsuruta Y, et al. Anti-inflammatory effects of hydrogen peroxide in neutrophil activation and acute lung injury. Am J Resp Crit Care Med 2009; 15: 694-704.
17. Saitoh S-I Zhang C, Tune JD, et al. Hydrogen peroxide. A feedforward dilator that couples myocardial metabolism to coronary blood flow. Arterioscler Thromb Vasc Biol 2006; 26: 2614-9.
18. Farr CH. The Therapeutic Use of Intravenous Hydrogen Peroxide (Monograph). Genesis Medical Center, Oklahoma City, OK 73139, 1987.
19. Dormandy TL. In praise of peroxidation. Lancet 1988; 12: 1126-8.
20. Atamna H, Kumar R. Protective role of methylene blue in Alzheimer's disease via mitochondria and cytochrome c oxidase. J Alzheimers Dis 2010; 20 Suppl.2: 439-52.
21. Bhattacharya RS, Husbeck B, Feldman D, Knox SJ. Selenite treatment inhibits LAPC-4 tumor growth and prostate-specific antigen secretion in a xenograft model of human prostate cancer. Int J Radiat Oncol Biol Phys 2008; 72: 935-40.
22. Bandura L, Drukala J, Wolnicka-Glubisz A, Bjornstedt M, Korodoha W. Differential effect ofselenite and selenate on human melanocytes, keratinocytes and melanoma cells. Biochem Cell Biol 2005; 83: 196-211.
23. Kralova V, Brigulova K, Cervinka M, Rudolf E. Antiproliferative and cytotoxic effects of sodium selenite in human colon cancer. Toxicol In Vitro 2009; 23: 1497-503.
24. Chen XJ, Duan FD, Zhang HH, Xiong Y, Wang J. Sodium seleniteinduced apoptosis mediated by ROS attack on human osteosarcoma U2OS cells. Biol Trace Elem Res 2012; 145(1): 1-9.
25. Lipinski B. Prostate cancer vaccines, fibrin and selenium: A conceptual review. Open Prostate Cancer J 2010; 3: 69-73.
26. Steinhubl SR. Why have antioxidants failed in clinical trials? Am J Cardiol 2008; 101: 14D-9D.
27. Halliwell B. Vitamin C:Antioxidant or pro-oxidant in vivo? Free Radic Res 1996; 25: 439-454.
28. Perera RM, Bardeesy N. Cancer: when antioxidants are bad. Nature 2011; 475: 43-4.
29. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997; 82: 291-5.
30. Gutteridge JM, Halliwell B. Antioxidants: Molecules, medicines, and myths. Biochem Biophys Res Commun 2010; 293: 561-4.